Immunotherapy in earlier stage non small cell lung cancer (NSCLC) has the potential to make the biggest impact on improving overall survival outcomes, says a leading lung cancer expert who is pushing for a shift in research priorities and regulatory approval in the setting. Medical oncologist and NSCLC specialist Professor Nick Pavlakis says that immunotherapy ...
Immunotherapy could have biggest impact on earlier-stage NSCLC: Professor Nick Pavlakis
By Sunalie Silva
27 Sep 2021